ArticleInfection and drug resistance2020
Characterization of the IncFII-IncFIB(pB171) Plasmid Carrying
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Antimicrobial Resistance and Comparative Genome Analysis of High-RiskMicroorganisms · 2026Article
- Emergence of NDM-5-producing ST405 and NDM-1-producing ST10 Escherichia coli in bloodstream infections in Apulia, Italy, 2023-2025.Scientific reports · 2026Article
- Comparative genomic analyses ofmSystems · 2026Article
- Human-associated NDM-5-producing multidrug-resistantFrontiers in bioinformatics · 2026Article
- The emergence of highly resistant and hypervirulentEmerging microbes & infections · 2025Article
- Genomic characterization of multidrug-resistantFrontiers in microbiology · 2025Article
- Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones ofLife (Basel, Switzerland) · 2022Review
- Co-Occurrence of β-Lactam and Aminoglycoside Resistance Determinants among Clinical and Environmental Isolates ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Characterization of NDM-5 Carbapenemase-Encoding Gene (Infection and drug resistance · 2022Article
- Emergence of IncHI2 Plasmid-Harboring blaNDM-5 from PorcinePathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNew Delhi metallo-β-lactamase 5 (NDM-5) shows stronger resistance to carbapenems and broad-spectrum cephalosporins than NDM-1 because NDM-5 differs from NDM-1 by two amino acid substitutions. In this study, our aim was to characterize a NDM-5-producing PATIENTS AND
methodsNDM-5-producing
resultsKY1497 was classified as ST405 by MLST, and core-genome phylogeny exhibited the closest lineage to the clinical isolates in Nepal (IOMTU605) and Canada (FDAARGOS_448). KY1497 harbors
conclusionWe characterized a novel Inc replicon plasmid (IncFII-IncFIB[pB171]) carrying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.